BETA
Medical-device developer working on a catheter-based nerve-ablation approach for congestive heart failure.
Corveus Medical is a Houston-based developer of catheter technology intended to interrupt nerve signaling involved in congestive heart failure. The company describes a minimally invasive approach rather than an implanted pump or a drug therapy.
Its leadership includes co-founders Tyler Melton and Ishan Kamat. Y Combinator lists the company as founded in 2021 and part of its Winter 2022 cohort. A marketed device and routine clinical availability have not been established in the reviewed sources.
Corveus describes its heart-failure catheter as a development program. No matching published 510(k), De Novo or original PMA decision was identified in the company-name searches; these findings do not establish whether confidential investigational submissions exist. [9][3][4][6][8]
No matching FDA recall or device-enforcement record was identified under Corveus. There is no marketed portfolio established in the reviewed material. [5][7]
Latest recorded source review: 2026-10-20.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Development program intended to reach and ablate a targeted nerve branch through a catheter-based procedure. Clinical benefit and routine availability are not established here. [9][1]
Investigational / in developmentAccessed 10/20/2026